Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation
therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA
(V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20
– 23, 2023 in Milan, Italy. The new data build on SNS-101’s preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. SNS-101
is currently in a Phase 1/2 clinical study.
Presentation Details:
Title: SNS-101, a clinical-stage pH-dependent and TME-selective anti-VISTA antibody with favorable pharmacokinetic and safety characteristics, promotes anti-tumoral M1 macrophage
polarization in PD-1 refractory settings
Presentation Type: Poster
Date and Time: Thursday, September 21, 2023, from 12:30 pm to 2:00 pm CET
Session: Poster Session A
The poster will be made available on the Sensei Bio website following the presentation.
Lesen Sie auch
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb
(Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is
also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal
antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.